Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon N versus Creon in cystic fibrosis-related pancreatic exocrine insufficiency
2013-002819-10Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Oct 2013
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pancreatin in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Coefficient of fat absorption. Started Oct 2013; status: completed.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2013-002819-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002819-10.